Who are Approved Hypertrophic Cardiomyopathy drug treatments's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Perindopril + amlodipine + if necessary, hydrochlorothiazide, Lotrel (amlodipine/benazepril), Losartan and amlodipine and hydrochlorothiazide, Perindopril plus Amlodipine, Calcium Channel Blockers, ACE-Inhibitor, Treatment R.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/approved-hypertrophic-cardiomyopathy-drug-treatments.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Approved Hypertrophic Cardiomyopathy drug treatments — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Approved Hypertrophic Cardiomyopathy drug treatments (Approved Hypertrophic Cardiomyopathy drug treatments) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcium channel blocker. Area: Cardiovascular.

phase 2 Calcium channel blocker L-type calcium channels Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Approved Hypertrophic Cardiomyopathy drug treatments (Approved Hypertrophic Cardiomyopathy drug treatments) — Bristol-Myers Squibb. Calcium channel blocker

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Approved Hypertrophic Cardiomyopathy drug treatments TARGET	Approved Hypertrophic Cardiomyopathy drug treatments	Bristol-Myers Squibb	phase 2	Calcium channel blocker	L-type calcium channels
Perindopril + amlodipine + if necessary, hydrochlorothiazide	Perindopril + amlodipine + if necessary, hydrochlorothiazide	Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company	marketed	ACE inhibitor + calcium channel blocker + thiazide diuretic combination	Angiotensin-converting enzyme (ACE), L-type calcium channels, sodium-chloride cotransporter
Lotrel (amlodipine/benazepril)	Lotrel (amlodipine/benazepril)	Abbott	marketed	Calcium channel blocker / ACE inhibitor combination	L-type calcium channels (amlodipine); Angiotensin-converting enzyme (benazepril)
Losartan and amlodipine and hydrochlorothiazide	Losartan and amlodipine and hydrochlorothiazide	Hotel Dieu de France Hospital	marketed	Antihypertensive combination (ARB + calcium channel blocker + thiazide diuretic)	Angiotensin II type 1 receptor (AT1R), L-type calcium channels, sodium-chloride cotransporter
Perindopril plus Amlodipine	Perindopril plus Amlodipine	University of Abuja	marketed	ACE inhibitor + Calcium channel blocker combination	ACE (angiotensin-converting enzyme) and L-type calcium channels
Calcium Channel Blockers, ACE-Inhibitor	Calcium Channel Blockers, ACE-Inhibitor	University of Aarhus	marketed	Combination antihypertensive (calcium channel blocker + ACE inhibitor)	L-type calcium channels; Angiotensin-converting enzyme (ACE)
Treatment R	Treatment R	Boryung Pharmaceutical Co., Ltd	marketed	Calcium channel blocker	L-type calcium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcium channel blocker class)

Shenzhen Ausa Pharmed Co.,Ltd · 2 drugs in this class
Boryung Pharmaceutical Co., Ltd · 2 drugs in this class
Ain Shams University · 1 drug in this class
Bioprojet · 1 drug in this class
Bristol-Myers Squibb · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Handok Inc. · 1 drug in this class
Hasten Biopharmaceutical Co., Ltd. · 1 drug in this class
Hospital de Clinicas de Porto Alegre · 1 drug in this class
Laboratorios Richmond S.A.C.I.F. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Approved Hypertrophic Cardiomyopathy drug treatments — Competitive Intelligence Brief. https://druglandscape.com/ci/approved-hypertrophic-cardiomyopathy-drug-treatments. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab